Lexicon Narrows Losses on Novo Nordisk Deal, Cuts Spending

Ticker: LXRX · Form: 10-Q · Filed: Nov 6, 2025

Sentiment: mixed

Topics: Biotechnology, Pharmaceuticals, Licensing Agreement, Drug Development, Financial Performance, Cash Management, Obesity Treatment

Related Tickers: LXRX, NVO

TL;DR

**LXRX is finally getting its act together, slashing losses and landing a big pharma deal, making it a speculative buy for the long haul.**

AI Summary

Lexicon Pharmaceuticals, Inc. reported a significant reduction in net loss for the nine months ended September 30, 2025, decreasing to $34.8 million from $166.6 million in the prior year, primarily driven by a substantial increase in licensing revenue. Total revenues surged to $44.3 million for the nine months ended September 30, 2025, up from $4.5 million in the same period of 2024, largely due to a $45 million upfront payment from Novo Nordisk for the LX9851 license agreement. Net product revenue, however, declined to $3.6 million from $4.5 million year-over-year. Operating expenses saw a considerable decrease, falling to $78.4 million from $168.9 million, with R&D expenses decreasing to $49.8 million from $57.8 million and SG&A expenses dropping sharply to $28.6 million from $110.8 million. The company's cash and cash equivalents decreased to $49.7 million from $66.7 million, and short-term investments fell to $66.3 million from $171.3 million, reflecting net cash used in operating activities of $50.6 million. Long-term debt was reduced to $56.5 million from $100.3 million, with $45 million in debt repayments. The strategic outlook is centered on the LX9851 collaboration with Novo Nordisk, which provides significant potential milestone payments up to $960 million and tiered royalties.

Why It Matters

This 10-Q filing signals a pivotal shift for Lexicon Pharmaceuticals, as the substantial licensing deal with Novo Nordisk for LX9851 provides a much-needed cash infusion and validates their preclinical pipeline, potentially de-risking future development costs. For investors, the significant reduction in net loss and operating expenses, particularly SG&A, indicates improved financial discipline and a more sustainable burn rate, which is crucial for a biotech company. Employees may see increased stability and focus on the LX9851 program. In the competitive landscape, this partnership positions Lexicon to potentially capitalize on the lucrative obesity and cardiometabolic disorders market with a strong partner, while also freeing up resources to advance other internal programs. The market will be watching for further milestone achievements and clinical progress of LX9851.

Risk Assessment

Risk Level: medium — While Lexicon significantly reduced its net loss and operating expenses, the company still reported a net loss of $34.8 million for the nine months ended September 30, 2025. Cash and cash equivalents, along with short-term investments, decreased from $237.9 million at December 31, 2024, to $144.9 million at September 30, 2025, indicating continued cash burn. The company's future success heavily relies on the clinical and commercial success of LX9851, which is still in preclinical stages, and the achievement of contingent milestone payments from Novo Nordisk.

Analyst Insight

Investors should consider Lexicon Pharmaceuticals as a speculative growth play, given the significant de-risking provided by the Novo Nordisk collaboration and the improved financial efficiency. Monitor the progress of LX9851 through its clinical development stages and any announcements regarding milestone payments, as these will be key drivers for future valuation. The reduction in operating expenses suggests a more focused approach, but continued cash management will be critical.

Financial Highlights

debt To Equity
0.71
revenue
$44,310,000
operating Margin
-77.0%
total Assets
$205,927,000
total Debt
$56,508,000
net Income
$-34,811,000
eps
$-0.10
gross Margin
-1.9%
cash Position
$49,656,000
revenue Growth
+879.4%

Revenue Breakdown

SegmentRevenueGrowth
Licensing Revenue$40,698,000N/A
Net Product Revenue$3,592,000-19.3%
Royalties and Other Revenue$20,000-73.7%

Key Numbers

Key Players & Entities

FAQ

How did Lexicon Pharmaceuticals' revenue change in Q3 2025?

Lexicon Pharmaceuticals' total revenues for the nine months ended September 30, 2025, surged to $44.3 million, a substantial increase from $4.5 million in the same period of 2024. This was primarily driven by $40.7 million in licensing revenue, including a $45 million upfront payment from Novo Nordisk.

What was Lexicon Pharmaceuticals' net loss for the nine months ended September 30, 2025?

Lexicon Pharmaceuticals reported a net loss of $34.8 million for the nine months ended September 30, 2025. This represents a significant improvement compared to the net loss of $166.6 million for the same period in 2024.

What is the significance of the Novo Nordisk agreement for Lexicon Pharmaceuticals?

The exclusive license agreement with Novo Nordisk for LX9851 is highly significant. It provided Lexicon with an upfront payment of $45 million and offers potential milestone payments up to an aggregate of $960 million, plus tiered royalties. This partnership validates Lexicon's preclinical pipeline and provides crucial funding for future development.

How have Lexicon Pharmaceuticals' operating expenses changed?

Total operating expenses for Lexicon Pharmaceuticals decreased significantly to $78.4 million for the nine months ended September 30, 2025, down from $168.9 million in the prior year. This reduction was largely due to a sharp decrease in selling, general and administrative expenses, which fell to $28.6 million from $110.8 million.

What are the key risks for Lexicon Pharmaceuticals investors?

Key risks for Lexicon Pharmaceuticals investors include the continued net loss, reliance on the successful clinical development and commercialization of LX9851 by Novo Nordisk, and the uncertainty of achieving future milestone payments. The company's cash position, while improved by the licensing deal, still requires careful management.

What is LX9851 and its potential market?

LX9851 is Lexicon Pharmaceuticals' preclinical drug candidate for obesity and associated cardiometabolic disorders. The potential market for obesity and cardiometabolic treatments is substantial and growing, making the collaboration with Novo Nordisk in this area strategically important.

How much cash and cash equivalents does Lexicon Pharmaceuticals have?

As of September 30, 2025, Lexicon Pharmaceuticals had $49.7 million in cash and cash equivalents, a decrease from $66.7 million at December 31, 2024. Total cash, cash equivalents, and restricted cash stood at $78.7 million.

Did Lexicon Pharmaceuticals repay any debt in 2025?

Yes, Lexicon Pharmaceuticals made repayments of debt borrowings totaling $45.0 million during the nine months ended September 30, 2025. This reduced their long-term debt, net, to $56.5 million from $100.3 million at December 31, 2024.

What is Lexicon Pharmaceuticals' strategic outlook after the Novo Nordisk deal?

Lexicon Pharmaceuticals' strategic outlook is now heavily influenced by the Novo Nordisk collaboration, which provides significant non-dilutive funding and validates their drug discovery platform. The company will focus on completing IND-enabling activities for LX9851 and potentially advancing other internal pipeline candidates with a more stable financial foundation.

What impact did stock-based compensation have on Lexicon Pharmaceuticals' financials?

Stock-based compensation expense for Lexicon Pharmaceuticals was $9.7 million for the nine months ended September 30, 2025, compared to $12.0 million in the prior year. This non-cash expense is included in both research and development and selling, general and administrative costs.

Risk Factors

Industry Context

Lexicon Pharmaceuticals operates in the highly competitive biotechnology and pharmaceutical sector, focusing on developing treatments for serious unmet medical needs. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success often hinges on innovation, strategic partnerships for funding and commercialization, and the ability to navigate complex clinical trials and regulatory approvals.

Regulatory Implications

The company's drug development pipeline is subject to stringent regulatory oversight by agencies like the FDA. Any setbacks in clinical trials or manufacturing quality control can lead to significant delays, increased costs, and potential failure to gain market approval, impacting financial performance and investor confidence.

What Investors Should Do

  1. Monitor the progress of LX9851 clinical trials and regulatory submissions.
  2. Analyze the sustainability of reduced operating expenses.
  3. Evaluate the cash burn rate and runway.
  4. Track the recognition of future milestone and royalty payments from Novo Nordisk.

Key Dates

Glossary

Accumulated deficit
The cumulative net losses of a company since its inception, less any net earnings. It represents a deficit in the company's equity. (Indicates the company has historically operated at a loss, with the deficit decreasing in the current period due to increased revenue.)
Operating lease right-of-use-assets
An asset representing the right to use an underlying leased asset for the lease term, recognized under ASC 842. (Shows the company's obligations related to leased assets, which increased from $4.8 million to $7.5 million.)
Deferred revenue
Revenue that has been received by a company for goods or services that have not yet been delivered or rendered. (The emergence of $4.3 million in deferred revenue suggests future revenue streams from upfront payments or services yet to be fully recognized.)
Stock-based compensation
Compensation provided to employees in the form of stock options or awards, recognized as an expense. (Included in R&D and SG&A expenses, it shows a decrease in R&D stock-based compensation but a significant decrease in SG&A stock-based compensation year-over-year.)
Goodwill
An intangible asset that arises when one company acquires another for a price that is higher than the fair market value of its net assets. (Represents a significant intangible asset on the balance sheet, unchanged at $44.5 million.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Lexicon Pharmaceuticals has demonstrated a dramatic improvement in its financial performance, primarily driven by a significant increase in total revenues to $44.3 million from $4.5 million, largely due to a $45 million upfront payment from Novo Nordisk. This revenue surge has led to a substantial reduction in net loss, from $166.6 million to $34.8 million. Operating expenses have also been considerably curtailed, falling from $168.9 million to $78.4 million, with a particularly sharp decrease in SG&A expenses. However, cash and cash equivalents have decreased, and long-term debt has been reduced through significant repayments.

Filing Stats: 4,811 words · 19 min read · ~16 pages · Grade level 16.3 · Accepted 2025-11-06 16:10:33

Key Financial Figures

Filing Documents

– Financial Information

Part I – Financial Information 3

Financial Statements

Item 1. Financial Statements 3 Condensed Consolidated Balance Sheets - September 30, 2025 (unaudited) and December 31, 2024 3 Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) - Three and Nine Months Ended September 30, 2025 and 2024 4 Condensed Consolidated Statements of Stockholders' Equity (unaudited) - Three and Nine Months Ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Cash Flows (unaudited) - Nine Months Ended September 30, 2025 and 2024 7 Notes to Condensed Consolidated Financial Statements (unaudited) 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 17

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 22

Controls and Procedures

Item 4. Controls and Procedures 22

– Other Information

Part II – Other Information 24

Legal Proceedings

Item 1. Legal Proceedings 24

Risk Factors

Item 1A. Risk Factors 24

Other Information

Item 5. Other Information 27

Exhibits

Item 6. Exhibits 28

Signatures

Signatures 29 The Lexicon name and logo, INPEFA and ZYNQUISTA are registered trademarks of Lexicon Pharmaceuticals, Inc. —————— Factors Affecting Forward Looking Statements This quarterly report on Form 10-Q contains forward-looking statements. These statements relate to future events or our future financial performance. We have attempted to identify forward-looking statements by terminology including "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "should" or "will" or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under "Part II, Item 1A. - Risk Factors" and in our annual report on Form 10-K for the year ended December 31, 2024, that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels or activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, future results, levels of activity, performance or achievements may vary materially from our expectations. We are not undertaking any duty to update any of the forward-looking statements after the date of this quarterly report on Form 10-Q to conform these statements to actual results, unless required by law. 2

– Financial Information

Part I – Financial Information

Financial Statements

Item 1. Financial Statements Lexicon Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets (In thousands, except par value and share amounts) As of September 30, As of December 31, 2025 2024 Assets (unaudited) Current assets: Cash and cash equivalents $ 49,656 $ 66,656 Short-term investments 66,294 171,301 Accounts receivable, net 2,334 3,473 Inventory 158 231 Prepaid expenses and other current assets 4,085 4,532 Total current assets 122,527 246,193 Property and equipment, net 1,981 2,484 Goodwill 44,543 44,543 Operating lease right-of-use-assets 7,508 4,832 Restricted cash 29,000 — Other assets 368 368 Total assets $ 205,927 $ 298,420 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 3,797 $ 14,801 Accrued liabilities 13,620 30,447 Deferred revenue 4,303 — Total current liabilities 21,720 45,248 Long-term debt, net 56,508 100,298 Other long-term liabilities 7,540 6,924 Total liabilities 85,768 152,470 Commitments and contingencies (Note 7) Stockholders' Equity: Preferred stock, $ 0.01 par value; 5,000,000 shares authorized; 2,304,147 Series A Convertible Preferred shares issued and none outstanding — — Common stock, $ 0.001 par value; 450,000,000 shares authorized; 365,780,799 and 363,020,303 shares issued, respectively 366 363 Additional paid-in capital 2,127,005 2,117,325 Accumulated deficit ( 2,002,054 ) ( 1,967,242 ) Accumulated other comprehensive (loss) income 29 119 Treasury stock, at cost, 2,381,939 and 1,528,008 shares, respectively ( 5,187 ) ( 4,615 ) Total stockholders' equity 120,159 145,950 Total liabilities and stockholders' equity $ 205,927 $ 298,420 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Lexicon Pharmaceuticals, Inc. Condensed Consolidated Statements of Comprehensive Income (Loss) (In thousands, except per share amounts) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 20

View on Read The Filing